5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo

Clinical Neuropharmacology
G BersaniN Ciani

Abstract

Several studies support the hypothesis of 5-HT (serotonin) involvement in the physiopathology of the extrapyramidal system. Ritanserin is a new compound with a high, selective, and long-lasting binding affinity for 5-HT2 receptors. A therapeutic effect of ritanserin has been reported in Parkinson's tremor and L-Dopa-induced dyskinesias but no effect was seen in essential tremor. In this double-blind comparative study with orphenadrine (150 mg daily p.o.) and placebo, ritanserin (30 mg daily p.o.) was administered to 36 schizophrenic outpatients who were being treated with neuroleptic drugs and who had parkinsonism. For a period of 3 weeks, the treatment was added to the antipsychotic therapy after a 7-day washout from previous antiparkinson medication. Psychopathology was rated weekly by the Brief Psychiatric Rating Scale and showed no significant changes during the trial. The Mindham Rating Scale was used to assess symptoms of parkinsonism; at week 3, ritanserin was superior to orphenadrine (p less than 0.03) and to placebo (p less than 0.01). The results confirm previous observations of the therapeutic efficacy of ritanserin on neuroleptic-induced parkinsonism, and support the hypothesis that serotonin influences extrapyramid...Continue Reading

Citations

Aug 21, 1992·Pharmaceutisch Weekblad. Scientific Edition·A J Loonen
Mar 1, 1996·Psychopharmacology·B J Kinon, J A Lieberman
Jan 1, 1995·Life Sciences·C J SchmidtM G Palfreyman
Dec 19, 1996·European Journal of Pharmacology·S KongsamutA Sandrasagra
Jun 1, 2002·Ageing Research Reviews·Pietro GareriGiovambattista De Sarro
Apr 20, 1999·Pharmacology, Biochemistry, and Behavior·A M Montgomery, A J Grottick
Aug 25, 2000·Progress in Neuro-psychopharmacology & Biological Psychiatry·R BruggemanW Timmerman
Jan 1, 1999·Progress in Neurobiology·J D SalamoneA Nawab
Mar 23, 2000·Progress in Neurobiology·P GareriG De Sarro
Feb 1, 1997·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·C H MillerW W Fleischhacker
Mar 26, 2016·Progress in Neurobiology·Philippe De Deurwaerdère, Giuseppe Di Giovanni
Mar 14, 2007·International Review of Neurobiology·Anissa Abi-Dargham
Jan 1, 1997·Journal of Psychopharmacology·G F Busatto, R W Kerwin
Jan 16, 2010·Journal of Clinical Psychopharmacology·Wilma KnolRob J van Marum
Aug 27, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Robert M KesslerHerbert Y Meltzer
Jan 27, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·C H Miller, W W Fleischhacker
May 31, 2007·Clinical Drug Investigation·Pietro GareriGiovambattista De Sarro
Feb 28, 2003·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·H J Möller
Apr 21, 2010·The Journal of Pharmacology and Experimental Therapeutics·Tadashi IshibashiMitsutaka Nakamura
Dec 30, 2015·Movement Disorders Clinical Practice·Tay Kay YawAnthony E Lang
Aug 22, 2009·European Psychiatry : the Journal of the Association of European Psychiatrists·S AlmeidaS Frangou
Oct 1, 1993·The British Journal of Psychiatry : the Journal of Mental Science·S J DuinkerkeH L Busard
Nov 27, 2019·International Journal of Molecular Sciences·Gianluca Baldanzi, Mario Malerba
Jul 1, 2021·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Frederick M LangMarwan Noel Sabbagh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here